| Daratumumab, bortezomib, and dexamethasone for multiple myeloma A Palumbo, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... New England Journal of Medicine 375 (8), 754-766, 2016 | 1663 | 2016 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 437 | 2016 |
| Daratumumab-based treatment for immunoglobulin light-chain amyloidosis E Kastritis, G Palladini, MC Minnema, AD Wechalekar, A Jaccard, HC Lee, ... New England Journal of Medicine 385 (1), 46-58, 2021 | 361 | 2021 |
| Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study SK Kumar, MA Dimopoulos, E Kastritis, E Terpos, H Nahi, H Goldschmidt, ... Leukemia 31 (11), 2443-2448, 2017 | 325 | 2017 |
| Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ... Haematologica 103 (12), 2079, 2018 | 294 | 2018 |
| BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete-and overall-response rates in treatment-naive symptomatic … R Niesvizky, DS Jayabalan, PJ Christos, JR Furst, T Naib, S Ely, ... Blood, The Journal of the American Society of Hematology 111 (3), 1101-1109, 2008 | 232 | 2008 |
| Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis: a Center for International Blood and Marrow Transplant Research Study A D'Souza, A Dispenzieri, B Wirk, MJ Zhang, J Huang, MA Gertz, RA Kyle, ... Journal of Clinical Oncology 33 (32), 3741-3749, 2015 | 208 | 2015 |
| Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma R Niesvizky, S Ely, T Mark, S Aggarwal, JL Gabrilove, JJ Wright, ... Cancer 117 (2), 336-342, 2011 | 149 | 2011 |
| Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma T Mark, J Stern, JR Furst, D Jayabalan, F Zafar, A LaRow, RN Pearse, ... Biology of Blood and Marrow Transplantation 14 (7), 795-798, 2008 | 139 | 2008 |
| Lenalidomide‐induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment‐naive patients undergoing front‐line lenalidomide and … R Niesvizky, T Naib, PJ Christos, D Jayabalan, JR Furst, J Jalbrzikowski, ... British journal of haematology 138 (5), 640-643, 2007 | 114 | 2007 |
| Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report JR Schriber, PN Hari, KW Ahn, M Fei, LJ Costa, MA Kharfan‐Dabaja, ... Cancer 123 (16), 3141-3149, 2017 | 78 | 2017 |
| Early risks of death, stroke/systemic embolism, and major bleeding in patients with newly diagnosed atrial fibrillation: results from the GARFIELD-AF registry JP Bassand, S Virdone, SZ Goldhaber, AJ Camm, DA Fitzmaurice, ... Circulation 139 (6), 787-798, 2019 | 77 | 2019 |
| Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time SK Kumar, A Dispenzieri, R Fraser, F Mingwei, G Akpek, R Cornell, ... Leukemia 32 (4), 986-995, 2018 | 73 | 2018 |
| Clarithromycin (Biaxin)‐lenalidomide‐low‐dose dexamethasone (BiRd) versus lenalidomide‐low‐dose dexamethasone (Rd) for newly diagnosed myeloma F Gay, SV Rajkumar, M Coleman, S Kumar, T Mark, A Dispenzieri, ... American journal of hematology 85 (9), 664-669, 2010 | 67 | 2010 |
| Impact of prophylactic levofloxacin on rates of bloodstream infection and fever in neutropenic patients with multiple myeloma undergoing autologous hematopoietic stem cell … MJ Satlin, S Vardhana, R Soave, TB Shore, TM Mark, SE Jacobs, ... Biology of Blood and Marrow Transplantation 21 (10), 1808-1814, 2015 | 64 | 2015 |
| Atypical serum immunofixation patterns frequently emerge in immunomodulatory therapy and are associated with a high degree of response in multiple myeloma T Mark, D Jayabalan, M Coleman, RN Pearse, YL Wang, R Lent, ... British journal of haematology 143 (5), 654-660, 2008 | 61 | 2008 |
| Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma R Niesvizky, D Martínez-Baños, J Jalbrzikowski, P Christos, J Furst, ... Leukemia & lymphoma 48 (12), 2330-2337, 2007 | 61 | 2007 |
| Management and 1‐year outcomes of patients with newly diagnosed atrial fibrillation and chronic kidney disease: results from the prospective GARFIELD‐AF registry S Goto, P Angchaisuksiri, JP Bassand, AJ Camm, H Dominguez, ... Journal of the American Heart Association 8 (3), e010510, 2019 | 59 | 2019 |
| BiRd (clarithromycin, lenalidomide, dexamethasone): an update on long-term lenalidomide therapy in previously untreated patients with multiple myeloma A Rossi, T Mark, D Jayabalan, P Christos, F Zafar, K Pekle, R Pearse, ... Blood, The Journal of the American Society of Hematology 121 (11), 1982-1985, 2013 | 52 | 2013 |
| Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial P Sonneveld, A Chanan-Khan, K Weisel, AK Nooka, T Masszi, M Beksac, ... Journal of Clinical Oncology 41 (8), 1600-1609, 2023 | 50 | 2023 |
Daniel SherbenouAssociate Professor of Medicine, University of Colorado Anschutz Medical CampusVerified email at ucdenver.edu
